[go: up one dir, main page]

SE9901634D0 - Treatment of myocardial infarction with a substance related to the growth hormone axis - Google Patents

Treatment of myocardial infarction with a substance related to the growth hormone axis

Info

Publication number
SE9901634D0
SE9901634D0 SE9901634A SE9901634A SE9901634D0 SE 9901634 D0 SE9901634 D0 SE 9901634D0 SE 9901634 A SE9901634 A SE 9901634A SE 9901634 A SE9901634 A SE 9901634A SE 9901634 D0 SE9901634 D0 SE 9901634D0
Authority
SE
Sweden
Prior art keywords
growth hormone
treatment
myocardial infarction
substance related
axis
Prior art date
Application number
SE9901634A
Other languages
English (en)
Swedish (sv)
Inventor
Joergen Isgaard
Elmir Omerovic
Entela Bollano
Bengt-Aake Bengtsson
Original Assignee
Sahltech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sahltech Ab filed Critical Sahltech Ab
Priority to SE9901634A priority Critical patent/SE9901634D0/xx
Publication of SE9901634D0 publication Critical patent/SE9901634D0/xx
Priority to PCT/SE2000/000844 priority patent/WO2000067770A1/fr
Priority to AU47908/00A priority patent/AU4790800A/en
Priority to EP00930008A priority patent/EP1173190A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9901634A 1999-05-05 1999-05-05 Treatment of myocardial infarction with a substance related to the growth hormone axis SE9901634D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9901634A SE9901634D0 (sv) 1999-05-05 1999-05-05 Treatment of myocardial infarction with a substance related to the growth hormone axis
PCT/SE2000/000844 WO2000067770A1 (fr) 1999-05-05 2000-05-03 Traitement de l'infarctus myocardique aigu a l'aide d'une substance liee a l'axe de l'hormone de croissance
AU47908/00A AU4790800A (en) 1999-05-05 2000-05-03 Treatment of acute myocardial infarction with a substance related to the growth hormone axis
EP00930008A EP1173190A1 (fr) 1999-05-05 2000-05-03 Traitement de l'infarctus myocardique aigu a l'aide d'une substance liee a l'axe de l'hormone de croissance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901634A SE9901634D0 (sv) 1999-05-05 1999-05-05 Treatment of myocardial infarction with a substance related to the growth hormone axis

Publications (1)

Publication Number Publication Date
SE9901634D0 true SE9901634D0 (sv) 1999-05-05

Family

ID=20415485

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901634A SE9901634D0 (sv) 1999-05-05 1999-05-05 Treatment of myocardial infarction with a substance related to the growth hormone axis

Country Status (4)

Country Link
EP (1) EP1173190A1 (fr)
AU (1) AU4790800A (fr)
SE (1) SE9901634D0 (fr)
WO (1) WO2000067770A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785567B2 (en) 2002-08-23 2010-08-31 Valorisation-Recherche, Société en Commandite Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia
EP1529533A1 (fr) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Utilisation de sécrétagogues de l'hormone de croissance dans le traitement des lésions cérébrales ischémiques et hypoxiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
PT1007085E (pt) * 1997-07-04 2002-05-31 Pharmacia Ab Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao

Also Published As

Publication number Publication date
WO2000067770A1 (fr) 2000-11-16
EP1173190A1 (fr) 2002-01-23
AU4790800A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
HUP9901246A2 (hu) Növekedési hormon kiválasztását elősegítő vegyületek
WO2002015903A3 (fr) Nouvelle composition pharmaceutique permettant l'administration de n-0923
DE60043305D1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
GEP20043314B (en) Pharmaceutical Composition Comprising Entacapone, Levodopa, and Carbidopa
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
EP1186293A3 (fr) Administration intermittente d'un secretagogue d'hormone de croissance
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
HUP0203506A2 (hu) Terápiás ágensként használható módosított peptidek
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
ATE401892T1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
CA2326517A1 (fr) Nouvelles formes galeniques de meloxicame a administrer par voie orale
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
GR1002847B (el) Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
EP0177342A3 (fr) Formulations orales de protéines thérapeutiques
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
RU2004114865A (ru) Композиция и способ лечения диабета
JP2002530353A5 (fr)
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
WO2000048445A3 (fr) Composition pharmaceutique contenant de la desoxypeganine utilisee pour le traitement de la dependance a la nicotine
SE9901634D0 (sv) Treatment of myocardial infarction with a substance related to the growth hormone axis
DE50000864D1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
AU2907800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
EA199900438A1 (ru) Препарат местного применения для введения пептидных лекарственных средств в живые организмы